Label: DEXAMETHASONE SP- dexamethasone sodium phosphate injection, solution

  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Animal Drug Application

Drug Label Information

Updated January 2, 2019

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Dexamethasone-SP

    DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP 4MG/ML (equivalent to dexamethasone 3 mg/mL)

    FOR INTRAVENOUS USE IN HORSES ONLY

    WARNING: DO NOT USE IN HORSES INTENDED FOR FOOD

    FOR VETERINARY USE ONLY

    DESCRIPTION:Dexamethasone sodium phophate (a synthetic adrenocortical steroid), is a white or slightly yellow crystalline powder.  It is freely soluble in water and is exceedingly hygroscopic.  Each mL of sterile aqueous solution contains Dexamethasone Sodium Phosphate 4 mg (equivalent to dexamethasone 3 mg), Sodium Citrate 10 mg, Sodium Bisulfate 2 mg, Benzyl Alcohol 1.5% as a preservative, in Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid to adjust pH to between 7.0 and 8.5.

  • CLINICAL PHARMACOLOGY

    CLINICAL PHARMACOLOGY:

    Dexamethasone is a synthetic corticosteriod and possesses glucocorticoid activity.  Dexamethasone sodium phosphate is a salt of dexamethasone that is particularly suitable for intravenous administration because it is highly water soluble, permitting administration of relatively large doses in a small volume of diluent.  Dexamethasone, as a steroid, is equivalent in potency to some established steroids while being considerably more potent than others.  In the case of the dog, dexamethasone is found to be about equivalent in dosage to prednisone but about 30 to 40 times more potent than prednisolone.


  • INDICATIONS & USAGE

    INDICATIONS AND USAGE:

    Dexamethasone Sodium Phosphate Injection is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

  • CONTRAINDICATIONS

    CONTRAINDICATIONS:

    Do not use in viral infections.  Except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis.  Existence of congestive heart failure, osteoporosis and diabetes are relative contraindications.  In the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

  • WARNINGS

    WARNINGS:

    Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis.  Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate.  Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

  • PRECAUTIONS

    PRECAUTIONS:

    Because of the anti-inflammatory action of corticosteroids, signs of infection may be hidden and it may be necessary to stop treatment until diagnosis is made.  Overdosage of some glucocorticoids may result in sodium retention, fluid retention, potassium loss and weight gains.

    In infections characterized by overwhelming toxicity, dexamethasone sodium phosphate therapy, in conjunction with indicated antibacterial therapy, is effective in reducing mortality. It is essential that the causative organism be known and an effective antibacterial agent be administered concurrently.  The injudicious use of adrenal hormones in animals with infections can be hazardous.

    Use of corticosteroids, depending on dose, duration and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal.  In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations.

  • ADVERSE REACTIONS

    ADVERSE REACTIONS:

    The therapeutic use of dexamethasone sodium phosphate injection is unlikely to cause undesired accentuation of metabolic effects.  However, if continued corticosteroid therapy is anticipated, a high protein intake should be provided to keep the animal in positive nitrogen balance.  A retardant effect on wound healing should be considered when it is used in conjunction with surgery.  Euphoria or an improvement of attitude, and increased appetite are the usual manifestations.

    Side effects such as glycosuria, hyperglycemia, diarrhea, polydipsia and polyuria have been observed in some species.

    Side effects such as SAP and SGPT enzyme elevations, eosinopenia, and vomiting have occurred following use of synthetic corticosteroids in dogs.  Cushing's Syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

    Corticosteroids reportedly cause laminitis in horses.

  • DOSAGE & ADMINISTRATION

    DOSAGE AND ADMINISTRATION:  For Intravenous Use Only.

    Horses:  The usual intravenous dosage is 2.5 to 5 mg (based on 3 mg per mL of dexamethasone content).

    If permanent corticosteroid effect is required, oral therapy with dexamethasone may be substituted.  When therapy is to be withdrawn after prolonged corticosteroid administration, the daily dose should be reduced gradually over a number of days, in stepwise fashion.

  • HOW SUPPLIED

    HOW SUPPLIED:

    Dexamethasone-SP, dexamethasone sodium phosphate injection 4 mg/mL (equivalent to 3 mg/mL dexamethasone) is available in 100 mL multiple dose vials.

  • STORAGE AND HANDLING

    Store between 15°C and 30°C (59°F - 86°F).  Do not freeze.

  • PRECAUTIONS

    CAUTION:  Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • PRINCIPAL DISPLAY PANEL

    Label

  • INGREDIENTS AND APPEARANCE
    DEXAMETHASONE SP 
    dexamethasone sodium phosphate injection, solution
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:13985-043
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Dexamethasone Sodium Phosphate (UNII: AI9376Y64P) (Dexamethasone - UNII:7S5I7G3JQL) Dexamethasone3 mg  in 1 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:13985-043-29100 mL in 1 VIAL, MULTI-DOSE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANADAANADA20031704/29/2004
    Labeler - MWI/VetOne (019926120)
    Registrant - Bimeda, Inc. (060492923)
    Establishment
    NameAddressID/FEIBusiness Operations
    Bimeda-MTC256232216manufacture
    Establishment
    NameAddressID/FEIBusiness Operations
    Pharmacia and Upjohn Company LLC618054084api manufacture